Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$570433.2.

  • Ascendis Pharma A's Exchange Rate Effect fell 16431.52% to -$570433.2 in Q4 2025 from the same period last year, while for Dec 2025 it was -$13.0 million, marking a year-over-year decrease of 33656.48%. This contributed to the annual value of -$4.0 million for FY2025, which is 11643.16% down from last year.
  • Ascendis Pharma A's Exchange Rate Effect amounted to -$570433.2 in Q4 2025, which was down 16431.52% from -$1.8 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Exchange Rate Effect ranged from a high of $10.5 million in Q4 2021 and a low of -$9.0 million during Q1 2025
  • In the last 5 years, Ascendis Pharma A's Exchange Rate Effect had a median value of $54441.1 in 2024 and averaged $163312.6.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first surged by 146766.74% in 2021, then plummeted by 990363.14% in 2025.
  • Ascendis Pharma A's Exchange Rate Effect (Quarter) stood at $10.5 million in 2021, then tumbled by 78.54% to $2.3 million in 2022, then tumbled by 171.45% to -$1.6 million in 2023, then soared by 155.03% to $886934.1 in 2024, then crashed by 164.32% to -$570433.2 in 2025.
  • Its Exchange Rate Effect was -$570433.2 in Q4 2025, compared to -$1.8 million in Q3 2025 and -$1.6 million in Q2 2025.